Cambridge, United Kingdom
Svastia Genetics is a dynamic company specializing in precision genome analytics and novel patient data collections aimed at enhancing cancer treatment outcomes. Since its founding in 2019, the company has been at the forefront of combining clinical decision support with an expansive oncology knowledgebase to improve treatment selection and predict relapses in cancer therapy.
Based in the United Kingdom, Svastia Genetics operates within the realms of Analytics, Biotechnology, Data Analytics, Health Care, and Health and Wellness. The company offers over 300+ genetic analysis workflows, which are leveraged for advanced clinical trial design, patient selection, and stratification, making it a critical player in modernizing cancer research methodologies.
The startup has not been associated with any last investment or last investment investors as of the latest information available, indicating a potential opportunity for investors to engage in a promising venture within a high-impact sector.
